Sareum Regulatory News (SAR)

 Sareum Holdings PLC

("Sareum" or the "Company")

Sareum strengthens patent protection for lead programme SDC-1801

- Notice of Allowance from Japan Patent Office received

Cambridge, UK, 3 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the Japan Patent Office has issued a Notice of Allowance for a patent relating to SDC-1801, the Company's lead TYK2/JAK1 kinase inhibitor.

The newly approved Japanese patent, Special Application 2021-543577, safeguards SDC-1801 and its medical applications in treating inflammatory or immune disorders. This follows the earlier approval by the China National Intellectual Property Administration (CNIPA), which issued patent number CN113056456B for the same protections earlier this year. Patent applications in Europe (EP3864009), the US (US2021387981), and other territories are still under review.

The Company expects that the patent will be granted in the near future, subject to certain formalities being completed.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "The recent Notice of Allowance from the Japan Patent Office bolsters our growing confidence in SDC-1801, our lead TYK2/JAK1 kinase inhibitor. Our Phase 1a clinical trial in Australia is progressing well, and this latest patent recognition in Japan supports our intellectual property around this programme."

Further information on our patents can be found on our website at: https://sareum.com/patents/

-Ends-

For further information, please contact: 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com